12 / 28
Probability of overall survival
1.0
0.0
0.9
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
205
97
199
85
178
74
146
62
124
48
92
40
55
30
23
15
11
5
6
2
0
0
N at risk
Olaparib
TPC
Time from randomisation (months)
Robson ME. AACR 2018
Olaparib does not seem to improve OS in gBRCAm
metastic breast cancer
Olaparib
TPC
n
205
97
Median PFS
19.3 m 17.1 m
HR = 0.90
95% CI (0.66, 1.23)
p=0.513
Olaparib 300 mg bd (N=205)
TPC (N=97)